Abliva
Climate Impact & Sustainability Data (2022)
Reporting Period: 2022
Environmental Metrics
Climate Goals & Targets
Long-term Goals:
- Potential launch of KL1333 in 2027 (subject to successful clinical trials and regulatory approvals).
Medium-term Goals:
- Present interim analysis of the first 40 patients in late 2023 or early 2024.
Short-term Goals:
- Complete recruitment of the first 40 patients for the FALCON study by mid-2023.
Environmental Challenges
- Recruiting patients for clinical trials due to the rarity of the disease (primary mitochondrial disease) and the lengthy screening process (2-3 months per patient).
- Competition from other ongoing studies targeting the same patient population.
- High risk of severe COVID-19 infection among PMD patients, impacting recruitment and clinical trial conduct.
Mitigation Strategies
- Partnership with ICON Clinical Research (a large CRO) to manage the complexities of clinical trials.
- Securing funding through capital raises (200 million SEK) to support the FALCON study.